Shanghai Shyndec Pharmaceutical (SHA:600420) subsidiary Sinopharm Rongsheng obtained drug registration for bumetanide injection issued by China's medical products administrator.
The drug is used to treat edema associated with conditions such as heart failure and hypertension, according to a Friday filing with the Shanghai bourse.